8 research outputs found
Tissue Reconstruction of Rabbit Aortas After Balloon Catheter Injury An Analysis of Histopathogenesis in Association with Matrix Degrading Enzymes
No full textAnalysis of Lenvatinib’s Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma
No full textTransarterial chemoembolization (TACE) has been the standard treatment for intermediate-stage, unresectable hepatocellular carcinoma (u-HCC). However, with recent advances in systemic therapy and the emergence of the concept of TACE-refractory or -unsuitable, the effectiveness of systemic therapy, as well as TACE, has been demonstrated for patients judged to be TACE-refractory or -unsuitable. In this study, the efficacy of lenvatinib and its combination with TACE after lenvatinib was investigated in 140 patients with intermediate-stage u-HCC treated with lenvatinib mainly because of being judged to be TACE-refractory or -unsuitable. Median overall survival (OS) and progression-free survival (PFS) were 24.4 and 9.0 months, respectively, indicating a good response rate. In multivariate analysis, modified albumin–bilirubin (mALBI) grade and up to seven criteria were identified as independent factors for OS, and mALBI grade and tumor morphology were identified as independent factors for PFS. While 95% of all patients were TACE-refractory or -unsuitable, the further prognosis was prolonged by the combination with TACE after lenvatinib initiation. These findings suggest that systemic therapy should be considered for intermediate-stage u-HCC, even in patients judged to be TACE-refractory or -unsuitable. The use of TACE after the start of systemic therapy may further improve prognosis
Animal models on HTLV-1 and related viruses: What did we learn
No full textRetroviruses are associated with a wide variety of diseases, including immunological, neurological disorders, and different forms of cancer. Among retroviruses, Oncovirinae regroup according to their genetic structure and sequence, several related viruses such as human T-cell lymphotropic viruses types 1 and 2 (HTLV-1 and HTLV-2), simian T cell lymphotropic viruses types 1 and 2 (STLV-1 and STLV-2), and bovine leukemia virus (BLV). As in many diseases, animal models provide a useful tool for the studies of pathogenesis, treatment, and prevention. In the current review, an overview on different animal models used in the study of these viruses will be provided. A specific attention will be given to the HTLV-1 virus which is the causative agent of adult T-cell leukemia-lymphoma (ATL) but also of a number of inflammatory diseases regrouping the HTLV-associated myelopathy-tropical spastic paraparesis (HAM-TSP), infective dermatitis and some lung inflammatory diseases. Among these models, rabbits, monkeys but also rats provide an excellent in vivo tool for early HTLV-1 viral infection and transmission as well as the induced host immune response against the virus. But ideally, mice remain the most efficient method of studying human afflictions. Genetically altered mice including both transgenic and knockout mice, offer important models to test the role of specific viral and host genes in the development of HTLV-1-associated leukemia. The development of different strains of immunodeficient mice strains (SCID, NOD, and NOG SCID mice) provide a useful and rapid tool of humanized and xenografted mice models, to test new drugs and targeted therapy against HTLV-1-associated leukemia, to identify leukemia stem cells candidates but also to study the innate immunity mediated by the virus. All together, these animal models have revolutionized the biology of retroviruses, their manipulation of host genes and more importantly the potential ways to either prevent their infection or to treat their associated diseases. © 2012 El Hajj, Nasr, Kfoury, Dassouki, Nasser, Kchour, Hermine, de Thé and Bazarbachi.Abbaszadegan MR, 2003, J CLIN MICROBIOL, V41, P2593, DOI 10.1128-JCM.41.6.2593-2595.2003; Achachi A, 2005, P NATL ACAD SCI USA, V102, P10309, DOI 10.1073-pnas.0504248102; ADAM E, 1994, J VIROL, V68, P5845; Afonso PV, 2010, BLOOD, V116, P3802, DOI 10.1182-blood-2010-02-270751; Allan JS, 2001, CANCER INVEST, V19, P383, DOI 10.1081-CNV-100103133; Altanerova V, 2004, VIROLOGY, V329, P434, DOI 10.1016-j.virol.2004.09.001; ALTANEROVA V, 1989, J GEN VIROL, V70, P1929, DOI 10.1099-0022-1317-70-7-1929; ALTANEROVA V, 1990, Archiv fuer Geschwulstforschung, V60, P89; Arnold J, 2008, BLOOD, V112, P3788, DOI 10.1182-blood-2008-04-154286; Arnulf B, 2002, BLOOD, V100, P4129, DOI 10.1182-blood-2001-12-0372; Azakami K, 2009, BLOOD, V114, P3208, DOI 10.1182-blood-2009-02-203042; Azran I, 2005, ONCOGENE, V24, P4521, DOI 10.1038-sj.onc.1208645; Banerjee P, 2010, BLOOD, V115, P2640, DOI 10.1182-blood-2009-10-246959; Bartoe JT, 2000, J VIROL, V74, P1094, DOI 10.1128-JVI.74.3.1094-1100.2000; Bazarbachi A, 2010, J CLIN ONCOL, V28, P4177, DOI 10.1200-JCO.2010.28.0669; Bazarbachi A, 1999, BLOOD, V93, P278; Bazarbachi A, 2001, VIRUS RES, V78, P79, DOI 10.1016-S0168-1702(01)00286-6; Bazarbachi A, 2004, LANCET ONCOL, V5, P664, DOI 10.1016-S1470-2045(04)01608-0; BENVENISTY N, 1992, ONCOGENE, V7, P2399; BorisLawrie K, 1997, J VIROL, V71, P1514; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038-301527a0; Bouzar AB, 2009, BRIT J HAEMATOL, V144, P41, DOI 10.1111-j.1365-2141.2008.07426.x; Boxus M, 2009, BRIT J CANCER, V101, P1497, DOI 10.1038-sj.bjc.6605345; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006-viro.1997.8509; BREZIN AP, 1995, LANCET, V345, P1246, DOI 10.1016-S0140-6736(95)92033-1; BURNY A, 1985, ONDERSTEPOORT J VET, V52, P133; BURNY A, 1988, VET MICROBIOL, V17, P197, DOI 10.1016-0378-1135(88)90066-1; BURNY A, 1987, CANCER SURV, V6, P139; Calattini S, 2005, RETROVIROLOGY, V2, DOI 10.1186-1742-4690-2-30; Calomme C, 2004, J VIROL, V78, P13848, DOI 10.1128-JVI.78.24.13848-13864.2004; Chen J, 2009, BLOOD, V113, P1287, DOI 10.1182-blood-2008-04-149658; Christianson SW, 1997, J IMMUNOL, V158, P3578; Collins ND, 1998, BLOOD, V91, P4701; DANIEL MD, 1988, INT J CANCER, V41, P601, DOI 10.1002-ijc.2910410421; Debacq C, 2002, P NATL ACAD SCI USA, V99, P10048, DOI 10.1073-pnas.142100999; Debacq Christophe, 2004, Retrovirology, V1, P31, DOI 10.1186-1742-4690-1-31; Dewan MZ, 2003, J VIROL, V77, P5286, DOI 10.1128-JVI.77.9.5286-5294.2003; Dezzutti C. S., 1987, NATURE, V328, P543; DJILALI S, 1989, VET IMMUNOL IMMUNOP, V22, P233, DOI 10.1016-0165-2427(89)90010-X; DJILALI S, 1987, LEUKEMIA, V1, P777; Ego T, 2002, ONCOGENE, V21, P7241, DOI 10.1038-sj.onc.1205701; El Hajj H, 2010, J EXP MED, V207, P2785, DOI 10.1084-jem.20101095; El-Sabban ME, 2002, BLOOD, V99, P3383, DOI 10.1182-blood.V99.9.3383; El-Sabban ME, 2000, BLOOD, V96, P2849; FERRER JF, 1978, ANN RECH VET, V9, P803; Ferrer J F, 1980, Adv Vet Sci Comp Med, V24, P1; Feuer G, 1996, J VIROL, V70, P4038; FEUER G, 1995, J VIROL, V69, P1328; FEUER G, 1993, BLOOD, V82, P722; Florins A, 2009, PLOS ONE, V4, DOI 10.1371-journal.pone.0006943; Florins A, 2007, J VIROL, V81, P10195, DOI 10.1128-JVI.01058-07; FRANCHINI G, 1995, BLOOD, V86, P3619; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101-gad.6.11.2066; Fujii MI, 2000, AIDS RES HUM RETROV, V16, P1603, DOI 10.1089-08892220050193029; Fultz PN, 1999, J INFECT DIS, V179, P600, DOI 10.1086-314627; Gao L, 2005, BLOOD, V106, P4294, DOI 10.1182-blood-2005-04-1730; Gatza ML, 2003, ONCOGENE, V22, P5141, DOI 10.1038-sj.onc.1206549; Gatza ML, 2006, J VIROL, V80, P6657, DOI 10.1128-JVI.02270-05; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128-JVI.76.24.12813-12822.2002; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157; GESSAIN A, 1985, LANCET, V2, P407; Gessain A, 2000, B SOC PATHOL EXOT, V93, P163; Gillet N, 2007, RETROVIROLOGY, V4, DOI 10.1186-1742-4690-4-18; Good LF, 1996, J VIROL, V70, P2730; Gordon SN, 2010, J VIROL, V84, P3043, DOI 10.1128-JVI.01655-09; GOUBAU P, 1994, P NATL ACAD SCI USA, V91, P2848, DOI 10.1073-pnas.91.7.2848; GOUT O, 1990, NEW ENGL J MED, V322, P383, DOI 10.1056-NEJM199002083220607; Grange MP, 2000, J VIROL, V74, P11734, DOI 10.1128-JVI.74.24.11734-11743.2000; GRASSMANN R, 1992, J VIROL, V66, P4570; GREINER DL, 1995, AM J PATHOL, V146, P888; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073-pnas.92.4.1057; GUPTA P, 1982, SCIENCE, V215, P405, DOI 10.1126-science.6276975; Hakata Y, 2001, J VIROL, V75, P11515, DOI 10.1128-JVI.75.23.11515-11525.2001; Hall AP, 1998, J PATHOL, V186, P209; Hasegawa H, 2006, NAT MED, V12, P466, DOI 10.1038-nm1389; Haynes RP, 2010, J AGR ENVIRON ETHIC, V23, P1, DOI 10.1007-s10806-009-9206-1; Hermine O, 2004, HEMATOL J, V5, P130, DOI 10.1038-sj.thj.6200374; Hermine O, 1998, BIODRUGS, V10, P447, DOI 10.2165-00063030-199810060-00003; HESSELTON RM, 1995, J INFECT DIS, V172, P974; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073-pnas.78.10.6476; HINUMA Y, 1982, INT J CANCER, V29, P631, DOI 10.1002-ijc.2910290606; ISHIHARA S, 1992, JPN J CANCER RES, V83, P320; Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182-blood-2005-02-0516; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182-blood-2001-12-0207; Ito M, 2008, CURR TOP MICROBIOL, V324, P53; Jeang KT, 2010, ONCOTARGET, V1, P453; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074-jbc.R400009200; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126-science.2309119; Jin DY, 1998, CELL, V93, P81, DOI 10.1016-S0092-8674(00)81148-4; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126-science.6981847; Kannian P, 2010, VIRUSES-BASEL, V2, P2037, DOI 10.3390-v2092037; KAPLAN JE, 1993, REV MED VIROL, V3, P137, DOI 10.1002-rmv.1980030304; Karube K, 2004, BRIT J HAEMATOL, V126, P81, DOI 10.1111-j.1365-2141.2004.04999.x; KASHMIRI SVS, 1985, BIOCHEM BIOPH RES CO, V129, P126, DOI 10.1016-0006-291X(85)91412-3; Kawaguchi A, 2009, BLOOD, V114, P2961, DOI 10.1182-blood-2008-11-189308; Kawano N, 2005, LEUKEMIA, V19, P1384, DOI 10.1038-sj.leu.2403829; Kchour G, 2009, BLOOD, V113, P6528, DOI 10.1182-blood-2009-03-211821; Kerkhofs P, 1996, J VIROL, V70, P2170; Kerkhofs P, 2000, J GEN VIROL, V81, P957; Kettmann R., 1994, RETROVIRIDAE, V3, P39; KETTMANN R, 1976, P NATL ACAD SCI USA, V73, P1014, DOI 10.1073-pnas.73.4.1014; KETTMANN R, 1980, LEUKEMIA RES, V4, P509, DOI 10.1016-0145-2126(80)90062-4; Kfoury Y, 2012, ADV CANCER RES, V113, P85, DOI 10.1016-B978-0-12-394280-7.00003-8; Kfoury Y., 2005, CELL DEATH DIFFER; Kfoury Y, 2008, ONCOGENE, V27, P1665, DOI 10.1038-sj.onc.1210804; Kfoury Y, 2011, BLOOD, V117, P190, DOI 10.1182-blood-2010-05-285742; Kibler KV, 2001, J VIROL, V75, P2161, DOI 10.1128-JVI.75.5.2161-2173.2001; Klener P, 2006, J VIROL, V80, P1922, DOI 10.1128-JVI.80.4.1922-1938.2006; Kohno T, 2005, CANCER SCI, V96, P527, DOI 10.1111-j.1349-7006.2005.00080.x; KONDO A, 1993, BLOOD, V82, P2501; Kress AK, 2011, VIRUSES-BASEL, V3, P1439, DOI 10.3390-v3081439; Kucerova L, 1999, J VIROL, V73, P8160; Kwon H, 2005, J BIOL CHEM, V280, P35713, DOI 10.1074-jbc.M504848200; LAGARIAS DM, 1989, J VIROL, V63, P2099; Lairmore M., 2007, FIELDS VIROLOGY, V2, P2072; Lamsoul I, 2005, MOL CELL BIOL, V25, P10391, DOI 10.1128-MCB.25.23.10391-10406.2005; LAROCCA D, 1989, BIOCHEM BIOPH RES CO, V163, P1006, DOI 10.1016-0006-291X(89)92322-X; LAZO A, 1994, LEUKEMIA, V8, pS222; Lefebvre L, 2002, J VIROL, V76, P1400, DOI 10.1128-JVI.76.3.1400-1414.2002; Leisering A, 1871, BER VET W KGR SACHSE, V16, P15; Levin MC, 1997, NEW ENGL J MED, V336, P839, DOI 10.1056-NEJM199703203361205; Li XH, 2000, AIDS RES HUM RETROV, V16, P1583, DOI 10.1089-08892220050192994; Liu YX, 2002, LEUKEMIA RES, V26, P561, DOI 10.1016-S0145-2126(01)00169-2; Locatelli S, 2012, AIDS, V26, P659, DOI 10.1097-QAD.0b013e328350fb68; LOWENSTINE LJ, 1988, J ZOO WILDLIFE MED, V19, P168, DOI 10.2307-20094885; LOWENSTINE LJ, 1986, INT J CANCER, V38, P563, DOI 10.1002-ijc.2910380417; Lu HX, 2004, J VIROL, V78, P6735, DOI 10.1128-JVI.78.13.6735-6734.2004; Maeda N, 2010, CANCER SCI, V101, P224, DOI 10.1111-j.1349-7006.2009.01354.x; Mahieux R, 2011, VIRUSES-BASEL, V3, P1074, DOI 10.3390-v3071074; MAMMERICKX M, 1981, ZBL VET MED B, V28, P69; Marriott SJ, 2002, J BIOMED SCI, V9, P292, DOI 10.1159-000064998; Martin F, 2011, RETROVIROLOGY, V8, DOI 10.1186-1742-4690-8-86; Matsubara Y, 2005, LEUKEMIA, V19, P482, DOI 10.1038-sj.leu.2403628; Matsumoto K, 1997, J VIROL, V71, P4445; Matsuoka M, 2009, RETROVIROLOGY, V6, DOI 10.1186-1742-4690-6-71; Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038-nrc2111; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038-sj.onc.1206551; Meas S, 2002, VET MICROBIOL, V84, P275, DOI 10.1016-S0378-1135(01)00458-8; Meertens L, 2003, J VIROL, V77, P782, DOI 10.1128-JVI.77.1.782-789.2003; Meertens L, 2002, J VIROL, V76, P259, DOI 10.1128-JVI.76.1.259-268.2002; Meertens L, 2003, J GEN VIROL, V84, P2723, DOI 10.1099-vir.0.19253-0; Merezak C, 2002, J VIROL, V76, P5034, DOI 10.1128-JVI.76.10.5034-5042.2002; Merezak C, 2001, J VIROL, V75, P6977, DOI 10.1128-JVI.75.15.6977-6988.2001; Merimi M, 2007, RETROVIROLOGY, V4, DOI 10.1186-1742-4690-4-51; Merimi M, 2007, J VIROL, V81, P5929, DOI 10.1128-JVI.02606-06; Merimi Makram, 2009, Front Biosci (Schol Ed), V1, P154, DOI 10.2741-s15; Mitra-Kaushik S, 2004, BLOOD, V104, P3305, DOI 10.1182-blood-2004-01-0266; Miyazato P, 2006, J VIROL, V80, P10683, DOI 10.1128-JVI.01009-06; Mone A, 2005, BLOOD, V106, P3380, DOI 10.1182-blood-2005-01-0335; MOORE GRW, 1989, ANN NEUROL, V26, P523, DOI 10.1002-ana.410260405; Motton DD, 2003, J DAIRY SCI, V86, P2826, DOI 10.3168-jds.S0022-0302(03)73880-6; Murphy EL, 1997, J INFECT DIS, V176, P1468; Murphy EL, 1997, NEUROLOGY, V48, P315; Nagai Masahiro, 2003, Journal of Neurovirology, V9, P228, DOI 10.1080-713831478; Nasr R, 2003, BLOOD, V101, P4576, DOI 10.1182-blood-2002-09-2986; Nasr R, 2005, ONCOGENE, V24, P419, DOI 10.1038-sj.onc.1208212; Nasr R, 2006, BLOOD, V107, P4021, DOI 10.1182-blood-2005-09-3572; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126-science.2888190; NERENBERG MI, 1989, AM J PATHOL, V135, P1025; Nerrienet E, 2004, J GEN VIROL, V85, P25, DOI 10.1099-vir.0.19314-0; Nguyen TLA, 2004, J BIOL CHEM, V279, P35025, DOI 10.1074-jbc.M404081200; Nicot C, 2000, BLOOD, V96, P275; Nitta T, 2008, CANCER SCI, V99, P872, DOI 10.1111-j.1349-7006.2008.00766.x; Nomura M, 2004, J VIROL, V78, P3827, DOI 10.1128-JVI.78.8.3827-3836.2004; Novakovic S, 2004, J VIROL, V78, P8301, DOI 10.1128-jvi.78.15.8301-8311.2004; Ohashi T, 1999, J VIROL, V73, P6031; Ohsugi T, 2007, CANCER LETT, V257, P206, DOI 10.1016-j.canlet.2007.07.017; Ohsugi T, 2006, LEUKEMIA RES, V30, P90, DOI 10.1016-j.leukres.2005.06.001; Okayama A, 1997, J ACQ IMMUN DEF SYND, V15, P70; OKOCHI K, 1984, VOX SANG, V46, P245; OLSON C, 1981, J NATL CANCER I, V67, P671; Olson C., 1987, Enzootic bovine leukosis and bovine leukemia virus, P3; ONUMA M, 1990, VET MICROBIOL, V25, P131, DOI 10.1016-0378-1135(90)90072-4; ONUMA M, 1987, MICROBIOL IMMUNOL, V31, P131; OSAME M, 1986, LANCET, V1, P1031; Ott SL, 2003, PREV VET MED, V61, P249, DOI 10.1016-j.prevetmed.2003.08.003; Pearson T, 2008, CURR TOP MICROBIOL, V324, P25; Peloponese JM, 2004, J VIROL, V78, P11686, DOI 10.1128-JVI.78.21.11686-11695.2004; Phillips KE, 2000, CANCER RES, V60, P6977; Pierard V, 2010, J BIOL CHEM, V285, P19434, DOI 10.1074-jbc.M110.107607; Pise-Masison CA, 1998, J VIROL, V72, P1165; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073-pnas.77.12.7415; Portis T, 2001, J VIROL, V75, P2185, DOI 10.1128-JVI.75.5.2185-2193.2001; POWERS MA, 1991, J VIROL, V65, P4959; Rauch D, 2009, RETROVIROLOGY, V6, DOI 10.1186-1742-4690-6-116; Rhodes JK, 2003, J AM VET MED ASSOC, V223, P346, DOI 10.2460-javma.2003.223.346; Robek MD, 1999, J VIROL, V73, P4856; RODGERSJOHNSON P, 1985, LANCET, V2, P1247; Roncador G, 2005, LEUKEMIA, V19, P2247, DOI 10.1038-sj.leu.2403965; ROVNAK J, 1993, J VIROL, V67, P7096; RUDDLE NH, 1993, VIROLOGY, V197, P196, DOI 10.1006-viro.1993.1580; Saito M, 2009, RETROVIROLOGY, V6, DOI 10.1186-1742-4690-6-19; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016-j.cell.2008.05.009; Satou Y, 2004, LEUKEMIA, V18, P1357, DOI 10.1038-sj.leu.2403400; Satou Y, 2006, P NATL ACAD SCI USA, V103, P720, DOI 10.1073-pnas.0507631103; Satou Y, 2011, PLOS PATHOG, V7, DOI 10.1371-journal.ppat.1001274; SCHWARTZ I, 1994, VET RES, V25, P521; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111-j.1365-2141.1991.tb08051.x; SHIMOYAMA M, 1983, JPN J CLIN ONCOL, V13, P165; Shu ST, 2007, CANCER RES, V67, P11859, DOI 10.1158-0008-5472.CAN-07-1701; Shultz LD, 2005, J IMMUNOL, V174, P6477; Silverman LR, 2004, J VIROL, V78, P3837, DOI 10.1128-JVI.78.8.3837-3845.2004; Sintasath DM, 2009, EMERG INFECT DIS, V15, P175, DOI 10.3201-eid1502.080584; SLAMON DJ, 1984, SCIENCE, V226, P61, DOI 10.1126-science.6089351; Stewart SA, 1996, VIROLOGY, V226, P167, DOI 10.1006-viro.1996.0643; SUN SC, 1994, MOL CELL BIOL, V14, P7377; Sun SC, 2000, AIDS RES HUM RETROV, V16, P1591, DOI 10.1089-08892220050193001; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073-pnas.90.2.610; Suzuki Takeshi, 1997, Leukemia (Basingstoke), V11, P14; Swaims AY, 2010, BLOOD, V116, P2994, DOI 10.1182-blood-2009-07-231050; Szynal M, 2003, ONCOGENE, V22, P4531, DOI 10.1038-sj.onc.1206546; Tajima S, 1998, J VIROL, V72, P7569; Tajima S, 2000, J VIROL, V74, P10939, DOI 10.1128-JVI.74.23.10939-10949.2000; Tajima S, 2003, J VIROL, V77, P4423, DOI 10.1128-JVI.77.7.4423-4430.2003; Takajo I, 2007, INT J CANCER, V121, P2205, DOI 10.1002-ijc.22972; Takayanagi R, 2007, J VIROL, V81, P5908, DOI 10.1128-JVI.02811-06; Tana Watarai S., 2001, MICROBIOL IMMUNOL, V45, P447; Tanaka M, 2001, J VIROL, V75, P4420, DOI 10.1128-JVI.75.9.4420-4423.2001; Thomas A, 2010, AIDS RES HUM RETROV, V26, P33, DOI 10.1089-aid.2009.0124; Trono KG, 2001, VET MICROBIOL, V83, P235, DOI 10.1016-S0378-1135(01)00420-5; Tsukasaki K, 1999, BONE MARROW TRANSPL, V23, P87, DOI 10.1038-sj.bmt.1701533; Twizere JC, 2003, J NATL CANCER I, V95, P1846, DOI 10.1093-jnci-djg118; Uchiyama T, 1996, J CLIN IMMUNOL, V16, P305, DOI 10.1007-BF01541665; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074-jbc.273.33.21132; Valeri VW, 2010, BLOOD, V116, P3809, DOI 10.1182-blood-2010-05-284141; Van Brussel M, 1998, VIROLOGY, V243, P366, DOI 10.1006-viro.1998.9075; Van den Broeke A, 2010, LEUKEMIA RES, V34, P1663, DOI 10.1016-j.leukres.2010.06.003; Van den Broeke A, 2001, J VIROL, V75, P1095, DOI 10.1128-JVI.75.3.1095-1103.2001; VANDENBROEKE A, 1988, P NATL ACAD SCI USA, V85, P9263; Villaudy J, 2011, PLOS PATHOG, V7, DOI 10.1371-journal.ppat.1002231; Waldmann T. A., 1985, PRINCESS TAKAMATSU S, V15, P259; Welsh JS, 2011, ONCOLOGIST, V16, P1, DOI 10.1634-theoncologist.2010-0301; Willems L, 2000, AIDS RES HUM RETROV, V16, P1787, DOI 10.1089-08892220050193326; WILLEMS L, 1990, EMBO J, V9, P1577; WILLEMS L, 1999, CURRENT TOP VIROL, V1, P139; Willems L, 1997, J GEN VIROL, V78, P637; WILLEMS L, 1993, J VIROL, V67, P4078; Wolfe ND, 2005, P NATL ACAD SCI USA, V102, P7994, DOI 10.1073-pnas.0501734102; WYATT CR, 1989, J VIROL, V63, P4498; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074-jbc.M002970200; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093-emboj-20.23.6805; Yamagishi M, 2012, CANCER CELL, V21, P121, DOI 10.1016-j.ccr.2011.12.015; Yamaoka S, 1996, EMBO J, V15, P873; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016-S0092-8674(00)81466-X; Yamazaki J, 2009, BLOOD, V114, P2709, DOI 10.1182-blood-2008-08-174425; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016-S0092-8674(00)81447-6; Yoshida M, 2005, ONCOGENE, V24, P5931, DOI 10.1038-sj.onc.1208981; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073-pnas.81.8.2534; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073-pnas.79.6.2031; Zhang ML, 2005, BLOOD, V105, P1231, DOI 10.1182-blood-2004-05-1709; Zhang Z, 2003, CANCER RES, V63, P6453; Zhang Z, 2003, BLOOD, V102, P284, DOI 10.1182-blood-2002-11-3601; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073-pnas.89.15.7070; Zhao TM, 2005, RETROVIROLOGY, V2, DOI 10.1186-1742-4690-2-34; Zheng ZM, 2010, INT J BIOL SCI, V6, P730; Zimmerman B, 2010, VET PATHOL, V47, P677, DOI 10.1177-030098581037000972
GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide
No full textBackground: The Global Anticoagulant Registry in the FIELD–Atrial Fibrillation (GARFIELD-AF) is a worldwide non-interventional study of stroke prevention in patients with non-valvular AF. Methods and results: 52,080 patients with newly diagnosed AF were prospectively enrolled from 2010 to 2016. 4121 (7.9%) of these patients were recruited in DACH [Germany (n = 3567), Austria (n = 465) and Switzerland (n = 89) combined], and 47,959 patients were from 32 countries in other regions worldwide (ORW). Hypertension was most prevalent in DACH and ORW (85.3% and 75.6%, respectively). Diabetes, hypercholesterolaemia, carotid occlusive disease and vascular disease were more prevalent in DACH patients vs ORW (27.6%, 49.4%, 5.8% and 29.0% vs 21.7%, 40.9%, 2.8% and 24.5%). The use of non-vitamin K antagonist oral anticoagulants (NOACs) increased more in DACH over time. Management of vitamin K antagonists was suboptimal in DACH and ORW (time in therapeutic range of INR ≥ 65% in 44.6% and 44.4% of patients or ≥ 70% in 36.9% and 36.0% of patients, respectively). Adjusted rates of cardiovascular mortality and MI/ACS were higher in DACH while non-haemorrhagic stroke/systemic embolism was lower after 2-year follow-up. Conclusions: Similarities and dissimilarities in AF management and clinical outcomes are seen in DACH and ORW. The increased use of NOAC was associated with a mismatch of risk-adapted anticoagulation (over-and-undertreatment) in DACH. Suboptimal control of INR requires educational activities in both regional groups. Higher rates of cardiovascular death in DACH may reflect the higher risk profile of these patients and lower rates of non-haemorrhagic stroke could be associated with increased NOAC use. Graphical abstract: [Figure not available: see fulltext.]
Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data
No full textOBJECTIVE To investigate the clinical outcomes of patients who underwent cardioversion compared with those who did not have cardioverson in a large dataset of patients with recent onset non-valvular atrial fibrillation. DESIGN Observational study using prospectively collected registry data (Global Anticoagulant Registry in the FIELD-AF-GARFIELD-AF). SETTING 1317 participating sites in 35 countries. PARTICIPANTS 52 057 patients aged 18 years and older with newly diagnosed atrial fibrillation (up to six weeks' duration) and at least one investigator determined stroke risk factor. MAIN OUTCOME MEASURES Comparisons were made between patients who received cardioversion and those who had no cardioversion at baseline, and between patients who received direct current cardioversion and those who had pharmacological cardioversion. Overlap propensity weighting with Cox proportional hazards models was used to evaluate the effect of cardioversion on clinical endpoints (all cause mortality, non-haemorrhagic stroke or systemic embolism, and major bleeding), adjusting for baseline risk and patient selection. RESULTS 44 201 patients were included in the analysis comparing cardioversion and no cardioversion, and of these, 6595 (14.9%) underwent cardioversion at baseline. The propensity score weighted hazard ratio for all cause mortality in the cardioversion group was 0.74 (95% confidence interval 0.63 to 0.86) from baseline to one year follow-up and 0.77 (0.64 to 0.93) from one year to two year follow-up. Of the 6595 patients who had cardioversion at baseline, 299 had a follow-up cardioversion more than 48 days after enrolment. 7175 patients were assessed in the analysis comparing type of cardioversion: 2427 (33.8%) received pharmacological cardioversion and 4748 (66.2%) had direct current cardioversion. During one year follow-up, event rates (per 100 patient years) for all cause mortality in patients who received direct current and pharmacological cardioversion were 1.36 (1.13 to 1.64) and 1.70 (1.35 to 2.14), respectively. OBJECTIVE To investigate the clinical outcomes of patients who underwent cardioversion compared with those who did not have cardioverson in a large dataset of patients with recent onset non-valvular atrial fibrillation. DESIGN Observational study using prospectively collected registry data (Global Anticoagulant Registry in the FIELD-AF-GARFIELD-AF). SETTING 1317 participating sites in 35 countries. PARTICIPANTS 52 057 patients aged 18 years and older with newly diagnosed atrial fibrillation (up to six weeks' duration) and at least one investigator determined stroke risk factor. MAIN OUTCOME MEASURES Comparisons were made between patients who received cardioversion and those who had no cardioversion at baseline, and between patients who received direct current cardioversion and those who had pharmacological cardioversion. Overlap propensity weighting with Cox proportional hazards models was used to evaluate the effect of cardioversion on clinical endpoints (all cause mortality, non-haemorrhagic stroke or systemic embolism, and major bleeding), adjusting for baseline risk and patient selection. RESULTS 44 201 patients were included in the analysis comparing cardioversion and no cardioversion, and of these, 6595 (14.9%) underwent cardioversion at baseline. The propensity score weighted hazard ratio for all cause mortality in the cardioversion group was 0.74 (95% confidence interval 0.63 to 0.86) from baseline to one year follow-up and 0.77 (0.64 to 0.93) from one year to two year follow-up.Of the 6595 patients who had cardioversion at baseline, 299 had a follow-up cardioversion more than 48 days after enrolment. 7175 patients were assessed in the analysis comparing type of cardioversion: 2427 (33.8%) received pharmacological cardioversion and 4748 (66.2%) had direct current cardioversion. During one year follow-up, event rates (per 100 patient years) for all cause mortality in patients who received direct current and pharmacological cardioversion were 1.36 (1.13 to 1.64) and 1.70 (1.35 to 2.14), respectively. CONCLUSION In this large dataset of patients with recent onset non-valvular atrial fibrillation, a small proportion were treated with cardioversion. Direct current cardioversion was performed twice as often as pharmacological cardioversion, and there appeared to be no major difference in outcome events for these two cardioversion modalities. For the overall cardioversion group, after adjustments for confounders, a significantly lower risk of mortality was found in patients who received early cardioversion compared with those who did not receive early cardioversion. STUDY REGISTRATION ClinicalTrials.gov NCT01090362
Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF
No full textBACKGROUND: Many patients with atrial fibrillation have concomitant coronary artery disease with or without acute coronary syndromes and are in need of additional antithrombotic therapy. There are few data on the long-term clinical outcome of atrial fibrillation patients with a history of acute coronary syndrome. This is a 2-year study of atrial fibrillation patients with or without a history of acute coronary syndromes
GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide
No full textBackground The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is a worldwide non-interventional study of stroke prevention in patients with non-valvular AF.Methods and results 52,080 patients with newly diagnosed AF were prospectively enrolled from 2010 to 2016. 4121 (7.9%) of these patients were recruited in DACH [Germany (n= 3567), Austria (n=465) and Switzerland (n=89) combined], and 47,959 patients were from 32 countries in other regions worldwide (ORW). Hypertension was most prevalent in DACH and ORW (85.3% and 75.6%, respectively). Diabetes, hypercholesterolaemia, carotid occlusive disease and vascular disease were more prevalent in DACH patients vs ORW (27.6%, 49.4%, 5.8% and 29.0% vs 21.7%, 40.9%, 2.8% and 24.5%). The use of non-vitamin K antagonist oral anticoagulants (NOACs) increased more in DACH over time. Management of vitamin K antagonists was suboptimal in DACH and ORW (time in therapeutic range of INR >= 65% in 44.6% and 44.4% of patients or >= 70% in 36.9% and 36.0% of patients, respectively). Adjusted rates of cardiovascular mortality and MI/ACS were higher in DACH while non-haemorrhagic stroke/systemic embolism was lower after 2-year follow-up.Conclusions Similarities and dissimilarities in AF management and clinical outcomes are seen in DACH and ORW. The increased use of NOAC was associated with a mismatch of risk-adapted anticoagulation (over-and-undertreatment) in DACH. Suboptimal control of INR requires educational activities in both regional groups. Higher rates of cardiovascular death in DACH may reflect the higher risk profile of these patients and lower rates of non-haemorrhagic stroke could be associated with increased NOAC use.[GRAPHICS]
Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation A Report From the GARFIELD-AF Registry
No full textIMPORTANCE Congestive heart failure (CHF) is commonly associated with nonvalvular atrial fibrillation (AF), and their combination may affect treatment strategies and outcomes
